Nicox

NicOx is a French pharmaceutical company seeking to become an ophthalmology specialist. Its core nitric oxide-donating platform creates new versions of existing drugs. BOL-303259-X is entering Phase III trials for glaucoma in partnership with Bausch+Lomb.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Herantis Pharma – executive interview

Take on Trusts – April 2025

KEFI Gold and Copper – executive interview

About Edison

About Edison

Careers

Nicox (Euronext Growth: ALCOX)

Latest Insights

Nicox — Animal data show favourable profile vs Lumigan

Nicox — Q323 update confirms trajectory for NCX-470

Nicox — Denali trial remains on track for 2025 readout

Nicox — Nicox provides NCX-470 sales potential estimates

Sector

Nicox — NCX-470 non-inferior to latanoprost in Mont Blanc

Nicox — Looking ahead to Mont Blanc study readout

Nicox — Revising NCX-470 timelines given Denali delay

Nicox — Moving towards key Mont Blanc data in Q4

Nicox — Mont Blanc top-line data timelines pushed forward

Nicox — Eye health portfolio targets large markets

Nicox — New governance structure

Nicox – executive interview

Nicox — Funded through key milestones

Nicox — Mississippi data shows benefit in dry eye

Nicox — Commercial products continue to grow

Nicox — NCX-4251 setback sharpens focus on NCX-470

Nicox — Continuing to move towards data inflection points

Nicox — Key programmes continue to advance

Nicox — No surprises as NCX-470 Phase III trials advance

Nicox – Edison Open House interview

Nicox — Focus on sight